Linked Life Data

10705200

Source:http://linkedlifedata.com/resource/pubmed/id/10705200

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10705200rdf:typepubmed:Citationlld:pubmed
pubmed-article:10705200lifeskim:mentionsumls-concept:C1257890lld:lifeskim
pubmed-article:10705200lifeskim:mentionsumls-concept:C0376358lld:lifeskim
pubmed-article:10705200lifeskim:mentionsumls-concept:C0002844lld:lifeskim
pubmed-article:10705200lifeskim:mentionsumls-concept:C0023610lld:lifeskim
pubmed-article:10705200lifeskim:mentionsumls-concept:C0038952lld:lifeskim
pubmed-article:10705200lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:10705200lifeskim:mentionsumls-concept:C0000975lld:lifeskim
pubmed-article:10705200lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:10705200lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:10705200lifeskim:mentionsumls-concept:C0243071lld:lifeskim
pubmed-article:10705200lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:10705200lifeskim:mentionsumls-concept:C0332206lld:lifeskim
pubmed-article:10705200lifeskim:mentionsumls-concept:C0205088lld:lifeskim
pubmed-article:10705200lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:10705200lifeskim:mentionsumls-concept:C1512888lld:lifeskim
pubmed-article:10705200lifeskim:mentionsumls-concept:C0149473lld:lifeskim
pubmed-article:10705200pubmed:issue2lld:pubmed
pubmed-article:10705200pubmed:dateCreated2000-4-3lld:pubmed
pubmed-article:10705200pubmed:abstractTextThe aim of this study was to compare the effects of the nonsteroidal antiandrogen flutamide plus the LH-RH analogue goserelin acetate (combined androgen blockade [CAB]) with goserelin acetate alone in patients with advanced prostate cancer. The original analyses at 25 and 56 months of follow-up have been reported previously, and here we report the final survival analysis after 10 years of follow-up.lld:pubmed
pubmed-article:10705200pubmed:languageenglld:pubmed
pubmed-article:10705200pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10705200pubmed:citationSubsetIMlld:pubmed
pubmed-article:10705200pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10705200pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10705200pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10705200pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10705200pubmed:statusMEDLINElld:pubmed
pubmed-article:10705200pubmed:monthFeblld:pubmed
pubmed-article:10705200pubmed:issn0302-2838lld:pubmed
pubmed-article:10705200pubmed:authorpubmed-author:AltweinJ EJElld:pubmed
pubmed-article:10705200pubmed:authorpubmed-author:BoccardiLLlld:pubmed
pubmed-article:10705200pubmed:authorpubmed-author:LunglmayrGGlld:pubmed
pubmed-article:10705200pubmed:authorpubmed-author:HoldawayI MIMlld:pubmed
pubmed-article:10705200pubmed:authorpubmed-author:VarenhorstEElld:pubmed
pubmed-article:10705200pubmed:authorpubmed-author:HaefligerJ...lld:pubmed
pubmed-article:10705200pubmed:authorpubmed-author:TyrrellC JCJlld:pubmed
pubmed-article:10705200pubmed:authorpubmed-author:KlippelFFlld:pubmed
pubmed-article:10705200pubmed:authorpubmed-author:JordaanJ PJPlld:pubmed
pubmed-article:10705200pubmed:authorpubmed-author:Jurincic-Wink...lld:pubmed
pubmed-article:10705200pubmed:issnTypePrintlld:pubmed
pubmed-article:10705200pubmed:volume37lld:pubmed
pubmed-article:10705200pubmed:ownerNLMlld:pubmed
pubmed-article:10705200pubmed:authorsCompleteYlld:pubmed
pubmed-article:10705200pubmed:pagination205-11lld:pubmed
pubmed-article:10705200pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10705200pubmed:meshHeadingpubmed-meshheading:10705200...lld:pubmed
pubmed-article:10705200pubmed:meshHeadingpubmed-meshheading:10705200...lld:pubmed
pubmed-article:10705200pubmed:meshHeadingpubmed-meshheading:10705200...lld:pubmed
pubmed-article:10705200pubmed:meshHeadingpubmed-meshheading:10705200...lld:pubmed
pubmed-article:10705200pubmed:meshHeadingpubmed-meshheading:10705200...lld:pubmed
pubmed-article:10705200pubmed:meshHeadingpubmed-meshheading:10705200...lld:pubmed
pubmed-article:10705200pubmed:meshHeadingpubmed-meshheading:10705200...lld:pubmed
pubmed-article:10705200pubmed:meshHeadingpubmed-meshheading:10705200...lld:pubmed
pubmed-article:10705200pubmed:meshHeadingpubmed-meshheading:10705200...lld:pubmed
pubmed-article:10705200pubmed:meshHeadingpubmed-meshheading:10705200...lld:pubmed
pubmed-article:10705200pubmed:meshHeadingpubmed-meshheading:10705200...lld:pubmed
pubmed-article:10705200pubmed:meshHeadingpubmed-meshheading:10705200...lld:pubmed
pubmed-article:10705200pubmed:meshHeadingpubmed-meshheading:10705200...lld:pubmed
pubmed-article:10705200pubmed:meshHeadingpubmed-meshheading:10705200...lld:pubmed
pubmed-article:10705200pubmed:year2000lld:pubmed
pubmed-article:10705200pubmed:articleTitleComparison of an LH-RH analogue (Goeserelin acetate, 'Zoladex') with combined androgen blockade in advanced prostate cancer: final survival results of an international multicentre randomized-trial. International Prostate Cancer Study Group.lld:pubmed
pubmed-article:10705200pubmed:affiliationOncology Centre, Derriford Hospital, Plymouth, UK.lld:pubmed
pubmed-article:10705200pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10705200pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:10705200pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:10705200pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:10705200pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:10705200pubmed:publicationTypeMulticenter Studylld:pubmed